Complementing the elevated tumor angiogenic gene signatures observed with PBRM1 mutations (32, 33, 34), PBRM1 mutations in ccRCC patients are associated with improved response to antiangiogenic agents (32, 37, 38), the current standard of care for metastatic ccRCC in combination with immune checkpoint blockade (ICB) (39, 40). This evidence concerns the gene PBRM1 and nonpapillary renal cell carcinoma.